Literature DB >> 10067994

Longitudinal limb deficiencies and the sclerotomes. An analysis of 378 dysmelic malformations induced by thalidomide.

J McCredie1, H G Willert.   

Abstract

The pathogenesis of longitudinal reduction deformities of the limbs, or dysmelia, is still a matter of debate. Their morphological pattern was defined from a large collection of radiographs of children with dysmelia following the thalidomide disaster. We compared radiographs of 378 of these limbs with the sclerotomes which are areas of segmental sensory innervation of the limb skeleton defined by the radiation of referred pain. The pattern of dysmelia matched the sclerotomes closely in 279 limbs (73.5%). The principles of skeletal reduction in dysmelia are explained by the arrangement of the sclerotomes. The congruence between two separate and independent data sets shows that both patterns are expressions of the underlying segmental sensory innervation of the skeleton, and that the sensory nervous system is involved in the process of limb morphogenesis and teratogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067994     DOI: 10.1302/0301-620x.81b1.8448

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  8 in total

Review 1.  Amelia: a multi-center descriptive epidemiologic study in a large dataset from the International Clearinghouse for Birth Defects Surveillance and Research, and overview of the literature.

Authors:  Eva Bermejo-Sánchez; Lourdes Cuevas; Emmanuelle Amar; Marian K Bakker; Sebastiano Bianca; Fabrizio Bianchi; Mark A Canfield; Eduardo E Castilla; Maurizio Clementi; Guido Cocchi; Marcia L Feldkamp; Danielle Landau; Emanuele Leoncini; Zhu Li; R Brian Lowry; Pierpaolo Mastroiacovo; Osvaldo M Mutchinick; Anke Rissmann; Annukka Ritvanen; Gioacchino Scarano; Csaba Siffel; Elena Szabova; María-Luisa Martínez-Frías
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-10-14       Impact factor: 3.908

Review 2.  Phocomelia: a worldwide descriptive epidemiologic study in a large series of cases from the International Clearinghouse for Birth Defects Surveillance and Research, and overview of the literature.

Authors:  Eva Bermejo-Sánchez; Lourdes Cuevas; Emmanuelle Amar; Sebastiano Bianca; Fabrizio Bianchi; Lorenzo D Botto; Mark A Canfield; Eduardo E Castilla; Maurizio Clementi; Guido Cocchi; Danielle Landau; Emanuele Leoncini; Zhu Li; R Brian Lowry; Pierpaolo Mastroiacovo; Osvaldo M Mutchinick; Anke Rissmann; Annukka Ritvanen; Gioacchino Scarano; Csaba Siffel; Elena Szabova; María-Luisa Martínez-Frías
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-10-14       Impact factor: 3.908

3.  Constant inhibition in congenital lower extremity shortening: does it begin in utero?

Authors:  Andy Tsai; Tal Laor; Judy A Estroff; James R Kasser
Journal:  Pediatr Radiol       Date:  2018-05-24

Review 4.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Systematic radiographic evaluation of tibial hemimelia with orthopedic implications.

Authors:  Katia Kaplan-List; Nina B Klionsky; James O Sanders; Michael E Katz
Journal:  Pediatr Radiol       Date:  2017-01-03

6.  Assessment of nerve involvement in the lumbar spine: agreement between magnetic resonance imaging, physical examination and pain drawing findings.

Authors:  Bo C Bertilson; Eva Brosjö; Hans Billing; Lars-Erik Strender
Journal:  BMC Musculoskelet Disord       Date:  2010-09-10       Impact factor: 2.362

7.  Does transcutaneous electrical nerve stimulation (TENS) simultaneously combined with local heat and cold applications enhance pain relief compared with TENS alone in patients with knee osteoarthritis?

Authors:  Takaya Maeda; Hideki Yoshida; Tomoyuki Sasaki; Atsushi Oda
Journal:  J Phys Ther Sci       Date:  2017-10-21

Review 8.  Thalidomide and neurotrophism.

Authors:  Judith R Soper; S Fiona Bonar; Dudley J O'Sullivan; Janet McCredie; Hans-Georg Willert
Journal:  Skeletal Radiol       Date:  2018-10-19       Impact factor: 2.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.